Role of nanoparticles and nano-oxide particles in vaccine development
Paper Details
Role of nanoparticles and nano-oxide particles in vaccine development
Abstract
Nanotechnology is used in vaccine development especially in medical field for diagnosis of many diseases. Different nanoparticles during vaccine formulations designed for their use in promoting of the safe immune response. In order to increase antigen processing, various nanoparticles are used to advance immunity where they might be used as adjuvant. Nanotechnology widely used in medicine for diagnosis by developing nanoparticles of different composition, shapes and sizes. The development of vaccine proves to be very beneficial in the history of controlling diseases. Due to lack of understanding in vivo particular response of various nanoparticles that may operate as delivery system to increase antigen processing. This review provides most recent advances in field of nanovaccinology with the aim of uses of nanoparticles based antigen delivery vehicle and their use in medical field in treating of various diseases. Interaction of nanoparticles with cells of body immune system and their characteristics are discussed. There is need to more understanding of nanoparticles action in immune stimulatory, various delivery modes in addition to their behaviour in vivo and also designing of nanoparticles containing vaccines.
Akagi T, Baba M, Akashi M. 2011. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Advanced Polymer Science 247(1), 31-64.
Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. 2013. Targeting antigens to dendritic cell receptors for vaccine development. Drug Delivery 65, 22.
Chackerian B. 2007.Virus-like particles: flexible platforms for vaccine development.. Expert Review Vaccinces 6 (7), 381-390..
Chen YS, Hung YC, Liau I, Huang GS. 2009. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Research Letters 4(8), 858.
Chen YS, Hung YC, Lin WH, Huang GS. 2010. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21(19), 195.
Demento SL, Cui W, Criscione JM, Stern L, Tulipan J, Kaech SM, Fahmy TM. 2012.Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 33(19), 4957-4964.
Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. 2017. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Review Vaccines 16, 55–63.
Dunkle A, Blanchette C, Boone T, Corzett M, Fischer N, HoeprichP, Rasley A. 2013. Co-delivery of adjuvant and subunit antigens via a nanoparticle platform induces tissue-associated and systemic adaptive immune responses. Journal of Immunology 190(1), 4409.
Gupta PN, Vyas SP. 2011.Investigation of lectinized liposomes as M-cell targeted carrier adjuvant for mucosal immunization. Colloids and surfaces B. American Society of Tropical Medicine and Hygiene 82(1), 118-125.
Ishizaka ST, Hawkins LD. 2007.E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev.Vaccinces 6(5),773-784.
Kushnir N, Streatfield SJ, Yusibov V. 2012. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31(1), 58-83.
Lepenies B, Lee J, Sonkaria S. 2013. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Advanced Drug Delivery Review 65(9), 1271-1281.
Lugade AA, Bharali DJ, Pradhan V, Elkin G, Mousa SA. 2014.Single low-dose unadjuvanted HBsAg nanoparticle vaccine elicits robust. Durable immunity 9(7), 923-934.
Manish M, Rahi A, Kaur M, Bhatnagar R, Singh SA. 2013.Single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. Plos one 8(4), e61885.
Milicic A, Kaur R, Sandoval RA, Tang CK, Honeycutt J, Perrie Y, Hill AV. 2012.Small cationic DDA: TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. Plos one 7(3), 34255.
Mothe RA, Kolte PN, Vo T, Ferrari JD, Gelsinger TC, Won J, Chan VT, Ahmed S, Srinivasan A, Deitemeyer P. 2018. Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis. Frontiers Immunology l9, 281.
Nandedkar TD. 2009. Nanovaccines: recent developments in vaccination. Journal of Bioscience 4(6), 995-1003.
Niikura K, Matsunaga T, Suzuki T, Kobayashi S, Yamaguchi H, Orba Y, Ijiro K. 2013. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nanotechnology 7(5), 3926-3938.
Oyewumi MO, Kumar A, Cui Z. 2010. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Review Vaccinces 9(9),1095-1107.
Pinheiro M, Lúcio M, Lima JL, Reis S. 2011.Liposomes as drug delivery systems for the treatment of TB . Nanomedine 6(8),1413-1428.
Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N. 2014.Sinchaipanid ,Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine. AAPS Pharmaceutical Scientific Technology 15(2), 317-325.
Schneider LP, Schoonderwoerd AJ, Moutaftsi M, Howard RF, Reed SG, Jong EC, Teunissen MB. 2012. Teunissen, Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 30(28), 4216-4224.
Shah MA, Ali Z, Ahmad R, Qadri I, Fatima K. 2015. DNA mediated vaccines delivery through nanoparticles. Nanoscale Research Letters 15(1), 41-53.
Silva AL, Rosalia RA, Sazak A, CarstensM G, Ossendorp F, Oostendorp J, Jiskoot JW. 2012. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient CD8+ T cell activation. European Journal of Biopharmcay 83(3), 338-345.
Treanor JJ, Essink B, Hull S, Reed S, Izikson R, Patriarca P, Dunkle LM. 2013. M,Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+ GLA) adjuvant. Vaccine 31(48), 5760-5765.
Treuel L, Jiang X, Nienhaus GU. 2012. New views on cellular uptake and trafficking of manufactured nanoparticles. Journal of Royal Society of Interfernce 10(82), 09-39.
Wang T, Zou M, Jiang H, Ji Z, Gao P, Cheng G. 2011. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Euro.J.Pharm Biopharm 44(5), 653-659.
Wang Y. 2016. FDA’s regulatory science program for generic PLA/PLGA-based drug products. American pharmaceutical review 19, 5-9.
Syed Naeem Sajid, Jabir Ali, Shahbaz Shafiq, Sana Abdul Majeed, Amina Azam, Sadia Fiaz, Rabeea Laeeq, Muhammad Zulqarnain, Arzoo Rubab, Zeshan Haider, Waqas Ahmed, Muhammad Awais Hayder, Sadam Hussain Siddiqi (2019), Role of nanoparticles and nano-oxide particles in vaccine development; JBES, V15, N2, August, P95-100
https://innspub.net/role-of-nanoparticles-and-nano-oxide-particles-in-vaccine-development/
Copyright © 2019
By Authors and International
Network for Natural Sciences
(INNSPUB) https://innspub.net
This article is published under the terms of the
Creative Commons Attribution License 4.0